TrialSignal
Clinical trial intelligence report
Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02677246
Status
WITHDRAWN
Phase
Phase 1
Sponsor
St. Justine's Hospital
Executive brief
Investment-Ready Snapshot
This clinical trial aimed to evaluate the safety and efficacy of Denosumab in preventing bone complications in pediatric patients following allogenic hematopoietic stem cell transplantation. The study was conducted by St. Justine's Hospital and was designed to assess the maximum tolerable dose and biological activity of Denosumab, a drug that inhibits bone resorption.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02677246
Indication
Disorder Related to Bone Marrow Transplantation
Modality
monoclonal antibody
Target
Bone complications after bone marrow transplantation in children
Intervention
Denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.